Patients with Still's disease will continue to participate in a phase III clinical trial to evaluate the safety and immunogenicity of GNR-086, taken by patients who have completed participation in the CAN-AOSD-III clinical trial, sponsored by GENERIUM JSC, Russia
The opening of the center was held: patients with erosive GERD will participate in an international, multicenter, prospective, randomized, double–blind, actively controlled, parallel-group study to evaluate the efficacy and safety of tegoprazane, sponsored by Dr. Reddy's Laboratories Ltd, India.
A selection visit was successfully completed to participate in a clinical trial of a biological therapy drug for the treatment of patients with moderate to severe chronic plaque psoriasis, sponsored by Binnopharm Group LLC.
The opening of the center was held: patients with Still's disease will participate in a phase 3 multicenter study to evaluate the efficacy and safety of GNR-086 compared with Ilaris®, sponsored by GENERIUM Pharmaceutical Company, Russia.
